Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $158,400.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.68, for a total transaction of $110,400.00.
• On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $105,600.00.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.20 during trading on Friday, reaching $3.56. 20,760,068 shares of the company traded hands, compared to its average volume of 20,924,796. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -2.97 and a beta of 1.00. The stock’s 50 day moving average price is $3.34 and its two-hundred day moving average price is $3.64. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same period in the prior year, the firm posted ($0.50) EPS. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% compared to the same quarter last year. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $31,000. Integral Investment Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $41,000. MQS Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the first quarter worth $41,000. Finally, Allworth Financial LP lifted its stake in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after buying an additional 4,403 shares during the period. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Morgan Stanley lifted their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.